Nutrigenetics and prostate cancer: 2011 and beyond

Journal of Nutrigenetics and Nutrigenomics

Volumn 4, Issue 3, 2011, Pages 121-136

  Yuan, Yinan ^a   Ferguson, Lynnette R ^a,b,c  

^a Discipline of Nutrition   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer progression; Cancer risk; Complex chromosome rearrangements; Nutrients; Nutrigenetics; Prostate cancer; Single nucleotide polymorphisms

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 3 METHYLSULPHINYLPROPYL; 4 METHYLSULPHINYLBUTYL; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR BETA; GLUTATHIONE TRANSFERASE M1; HEPATOCYTE NUCLEAR FACTOR 1BETA; HISTAMINE; HOMEOBOX PROTEIN NKX 3.1; HOMEODOMAIN PROTEIN; JUXTAPOSED WITH ZINC FINGER PROTEIN 1; LYCOPENE; ORGANIC CATION TRANSPORTER 3; UNCLASSIFIED DRUG; XRCC1 PROTEIN; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GENE EXPRESSION; GENE INTERACTION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INFLAMMATION; METABOLIC REGULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; NUTRIGENETICS; NUTRIGENOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM;

GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; NUTRIGENOMICS; PROSTATIC NEOPLASMS;

EID: 79957820049     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000327902     Document Type: Review

References (195)

1. Griffiths K, Prezioso D, Turkes A, Denis LJ: The prevention of prostate cancer. Recent Results Cancer Res 2007; 175: 33-63.
2. Nelen V: Epidemiology of prostate cancer. Recent Results Cancer Res 2007; 175: 1-8.
3. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, et al: Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010; 19: 2869-2876.
4. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, et al: Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008; 101: 547-555. (Pubitemid 351199281)
5. Sneyd MJ: Ethnic differences in prostate cancer survival in New Zealand: A national study. Cancer Causes Control 2008; 19: 993-999.
6. Lophatananon A, Archer J, Easton D, Pocock R, Dearnaley D, Guy M, et al: Dietary fat and early-onset prostate cancer risk. Br J Nutr 2010; 103: 1375-1380.
7. Hu J, La Vecchia C, Gibbons L, Negri E, Mery L: Nutrients and risk of prostate cancer. Nutr Cancer 2010; 62: 710-718.
8. Szymanski KM, Wheeler DC, Mucci LA: Fish consumption and prostate cancer risk: A review and meta-analysis. Am J Clin Nutr 2010; 92: 1223-1233.
9. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, et al: Vegetables, fruits, legumes and prostate cancer: A multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 795-804. (Pubitemid 30660052)
10. Jain MG, Hislop GT, Howe GR, Ghadirian P: Plant foods, antioxidants, and prostate cancer risk: Findings from casecontrol studies in Canada. Nutr Cancer 1999; 34: 173-184. (Pubitemid 29511115)
11. Adlercreutz H: Epidemiology of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 12: 605-623. (Pubitemid 29261274)
12. Rose DP: Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 1997; 216: 224-233.
13. Norrish AE, Ferguson LR, Knize MG, Felton JS, Sharpe SJ, Jackson RT: Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 1999; 91: 2038-2044.
14. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM: Men who consume vegetable oils rich in monounsaturated fat: Their dietary patterns and risk of prostate cancer (New Zealand). Cancer Causes Control 2000; 11: 609-615. (Pubitemid 30636360)
15. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM: Prostate cancer and dietary carotenoids. Am J Epidemiol 2000; 151: 119-123. (Pubitemid 30463641)
16. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT: Prostate cancer risk and consumption of fish oils: A dietary biomarker-based case-control study. Br J Cancer 1999; 81: 1238-1242.
17. Divisi D, Di Tommaso S, Salvemini S, Garramone M, Crisci R: Diet and cancer. Acta Biomed 2006; 77: 118-123.
18. Gonzalez CA: Nutrition and cancer: The current epidemiological evidence. Br J Nutr 2006; 96(suppl 1):S42-S45.
19. Colloca G, Venturino A: The evolving role of familial history for prostate cancer. Acta Oncol 2011; 50: 14-24.
20. Alberti C: Hereditary/familial versus sporadic prostate cancer: Few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci 2010; 14: 31-41.
21. Hemminki K, Forsti A, Lorenzo Bermejo J: New cancer susceptibility loci: Population and familial risks. Int J Cancer 2008; 123: 1726-1729, erratum 2009; 124: 2250.
22. Camp NJ, Farnham JM, Cannon Albright LA: Genomic search for prostate cancer predisposition loci in Utah pedigrees. Prostate 2005; 65: 365-374. (Pubitemid 41759969)
23. Black DM, Solomon E: The search for the familial breast/ovarian cancer gene. Trends Genet 1993; 9: 22-26. (Pubitemid 23022566)
24. Porter DE, Dixon M, Smyth E, Steel CM: Breast cancer survival in BRCA1 carriers. Lancet 1993; 341: 184-185. (Pubitemid 23029347)
25. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689. (Pubitemid 120031871)
26. Beuten J, Gelfond JAL, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, et al: Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 2010; 19: 588-599.
27. Breyer JP, McReynolds KM, Yaspan BL, Bradley KM, Dupont WD, Smith JR: Genetic variants and prostate cancer risk: Candidate replication and exploration of viral restriction genes. Cancer Epidemiol Biomarkers Prev 2009; 18: 2137-2144.
28. Liu H, Wang B, Han C: Meta-analysis of genome-wide and replication association studies on prostate cancer. Prostate 2011; 71: 209-224.
29. Shelling AN, Ferguson LR: Genetic variation in human disease and a new role for copy number variants. Mutat Res 2007; 622: 33-41. (Pubitemid 47211176)
30. Zeegers MP, Khan HS, Schouten LJ, van Dijk BAC, Goldbohm RA, Schalken J, et al: Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. Eur J Hum Genet 2011; 19: 118-120.
31. Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, Fujioka T, et al: A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 2010; 19: 4265-4272.
32. Harries LW, Perry JRB, McCullagh P, Crundwell M: Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 2010; 10: 315.
33. Kim S-T, Cheng Y, Hsu F-C, Jin T, Kader AK, Zheng SL, et al: Prostate cancer risk-associated variants reported from genome-wide association studies: Meta-analysis and their contribution to genetic variation. Prostate 2010; 70: 1729-1738.
34. Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, et al: Evaluation of association of HNF1B variants with diverse cancers: Collaborative analysis of data from 19 genome-wide association studies. PLoS One 2010; 5:e10858.
35. Xu B, Wang J, Tong N, Mi Y, Min Z, Tao J, et al: A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 2010; 70: 1146-1152.
36. Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, et al: Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate 2010; 70: 425-432.
37. Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, Field H, Guy M, Al Olama AA, et al: Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 2010; 102: 414-418.
38. Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, et al: Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009; 18: 2145-2149.
39. Song H, Koessler T, Ahmed S, Ramus SJ, Kjaer SK, Dicioccio RA, et al: Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. Cancer Res 2008; 68: 8837-8842.
40. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al: Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315. (Pubitemid 351311773)
41. Cross D, McCarty C, Reding D: PS1-13: Using the PMRP cohort to develop a model for incorporating genetic and environmental factors into prostate cancer screening decisions. Clin Med Res 2010; 8: 192.
42. Simopoulos AP: Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: Their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med (Maywood) 2010; 235: 785-795.
43. Saini S, Majid S, Dahiya R: Diet, microRNAs and prostate cancer. Pharm Res 2010; 27: 1014-1026.
44. Steinbrecher A, Rohrmann S, Timofeeva M, Risch A, Jansen E, Linseisen J: Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 135-143.
45. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, et al: Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res 2009; 69: 8133-8140.
46. Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MCR, et al: Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res 2009; 69: 1877-1884.
47. Wang S, Wang F, Shi X, Dai J, Peng Y, Guo X, et al: Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur J Cancer 2009; 45: 2874-2881.
48. Reese AC, Fradet V, Witte JS: Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics 2009; 2: 149-158.
49. Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, et al: Association of variants in two vitamin E transport genes with circulating vitamin E concentrations and prostate cancer risk. Cancer Res 2009; 69: 1429-1438.
50. Fradet V, Cheng I, Casey G, Witte JS: Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res 2009; 15: 2559-2566.
51. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, et al: Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 2008; 29: 2335-2340.
52. Nelson EC, Rodriguez RL, Dawson K, Galvez AF, Evans CP: The interaction of genetic polymorphisms with lifestyle factors: Implications for the dietary prevention of prostate cancer. Nutr Cancer 2008; 60: 301-312. (Pubitemid 351601367)
53. Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, et al: Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One 2008; 3:e2568.
54. Hedelin M, Balter KA, Chang ET, Bellocco R, Klint A, Johansson JE, et al: Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 2006; 66: 1512-1520. (Pubitemid 44467833)
55. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H, et al: Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006; 15: 99-107.
56. Ishibe N, Sinha R, Hein DW, Kulldorff M, Strickland P, Fretland AJ, et al: Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002; 12: 145-150. (Pubitemid 34298918)
57. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willett WC, Hennekens CH, et al: A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998; 58: 3307-3311. (Pubitemid 28371070)
58. Sharma S, Cao X, Wilkens LR, Yamamoto J, Lum-Jones A, Henderson BE, et al: Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19: 1866-1870.
59. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA: NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis 2008; 11: 349-356.
60. Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R, et al: Evidence-based criteria in the nutritional context. Nutr Rev 2010; 68: 478-484.
61. Zeisel SH: A grand challenge for nutrigenomics. Front Genet 2010; 1: 1-3.
62. Ferguson LR: Dietary influences on mutagenesis - where is this field going? Environ Mol Mutagen 2010; 51: 909-918.
63. Ferguson LR: Meat and cancer. Meat Sci 2010; 84: 308-313.
64. Ferguson LR: Nutrigenomics approaches to functional foods. J Am Diet Assoc 2009; 109: 452-458.
65. Ferguson LR: Genome-wide association studies and diet. World Rev Nutr Diet 2010; 101: 8-14.
66. Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, Jacques P, et al: Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet 2009; 18: 4677-4687.
67. Safarinejad MR, Shafiei N, Safarinejad S: Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study. Prostate 2010; 70: 1645-1657.
68. Van Guelpen BR, Wiren SM, Bergh AR, Hallmans G, Stattin PE, Hultdin J: Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: A nested case-control study. Eur J Cancer Prev 2006; 15: 46-50. (Pubitemid 43048742)
69. Solis C, Veenema K, Ivanov AA, Tran S, Li R, Wang W, et al: Folate intake at RDA levels is inadequate for Mexican American men with the methylenetetrahydrofolate reductase 677TT genotype. J Nutr 2008; 138: 67-72.
70. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
71. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, et al: The 1298A- 1 C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409-415. (Pubitemid 32522922)
72. Bai JL, Zheng MH, Xia X, Ter-Minassian M, Chen YP, Chen F: MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Cancer 2009; 45: 1443-1449.
73. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, et al: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4864. (Pubitemid 26374419)
74. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al: Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-1102. (Pubitemid 27138608)
75. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269. (Pubitemid 46486616)
76. Chang B-L, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL, Meyers DA, et al: Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate 2005; 64: 356-361. (Pubitemid 41193248)
77. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A: Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin Nutr 2004; 79: 935-945. (Pubitemid 41095944)
78. McEntee MF, Whelan J: Dietary polyunsaturated fatty acids and colorectal neoplasia. Biomed Pharmacother 2002; 56: 380-387. (Pubitemid 35238055)
79. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al: Expression of cyclooxygenase-1 and cyclooxygenase- 2 in the human prostate. Urology 2000; 56: 671-676.
80. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, et al: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006; 119: 668-672. (Pubitemid 43955722)
81. Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, et al: Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 2007; 120: 398-405. (Pubitemid 44956853)
82. Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO, et al: Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006; 12: 1936-1941.
83. Li LC, Yeh CC, Nojima D, Dahiya R: Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 2000; 275: 682-689.
84. Ganry O: Phytoestrogens and prostate cancer risk. Prev Med 2005; 41: 1-6. (Pubitemid 40762576)
85. Adlercreutz H: Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ Health Perspect 1995; 103(suppl 7):103-112.
86. Nagata C, Inaba S, Kawakami N, Kakizoe T, Shimizu H: Inverse association of soy product intake with serum androgen and estrogen concentrations in Japanese men. Nutr Cancer 2000; 36: 14-18. (Pubitemid 30317830)
87. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA: Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002; 186: 89-99. (Pubitemid 34189782)
88. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H: Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 2004; 45: 245-251, discussion 251. (Pubitemid 38147834)
89. Lund TD, Munson DJ, Adlercreutz H, Handa RJ, Lephart ED: Androgen receptor expression in the rat prostate is down-regulated by dietary phytoestrogens. Reprod Biol Endocrinol 2004; 2: 5.
90. Barnes S: Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol Rev 2001; 23: 102-105. (Pubitemid 32906620)
91. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
92. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6: 733-743. (Pubitemid 27427630)
93. Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL: Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006; 66: 146-156.
94. Cohen JH, Kristal AR, Stanford JL: Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61-68. (Pubitemid 30082230)
95. Conaway CC, Getahun SM, Liebes LL, Pusateri DJ, Topham DK, Botero-Omary M, et al: Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli. Nutr Cancer 2000; 38: 168-178. (Pubitemid 32762016)
96. Gasper AV, Al-Janobi A, Smith JA, Bacon JR, Fortun P, Atherton C, et al: Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli. Am J Clin Nutr 2005; 82: 1283-1291. (Pubitemid 43779728)
97. Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, Zhang Y, et al: Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer 2004; 50: 206-213.
98. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H: Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801-807. (Pubitemid 38737870)
99. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-1530, erratum 2003; 12: 1119. (Pubitemid 36020002)
100. van Gils CH, Bostick RM, Stern MC, Taylor JA: Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: An example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev 2002; 11: 1279-1284. (Pubitemid 35340361)
101. Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY: Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol 2006; 175: 108-112. (Pubitemid 41797104)
102. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS: DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 23-29. (Pubitemid 38116616)
103. Lu QY, Hung JC, Heber D, Go VLW, Reuter VE, Cordon-Cardo C, et al: Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 749-756. (Pubitemid 32695154)
104. Heber D, Lu QY: Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 2002; 227: 920-923. (Pubitemid 35340348)
105. Pohar KS, Gong MC, Bahnson R, Miller EC, Clinton SK: Tomatoes, lycopene and prostate cancer: A clinician's guide for counseling those at risk for prostate cancer. World J Urol 2003; 21: 9-14. (Pubitemid 44175290)
106. Goodman M, Bostick RM, Ward KC, Terry PD, van Gils CH, Taylor JA, et al: Lycopene intake and prostate cancer risk: Effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer 2006; 55: 13-20. (Pubitemid 44477040)
107. Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, et al: Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278: 1251-1255. (Pubitemid 27435612)
108. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, et al: Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study. J Natl Cancer Inst 1997; 89: 955-959. (Pubitemid 27282068)
109. Silverman RH: Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805-1812. (Pubitemid 36258654)
110. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581-583. (Pubitemid 35435169)
111. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, et al: A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981-984. (Pubitemid 135750531)
112. Simard J, Dumont M, Soucy P, Labrie F: Perspective: Prostate cancer susceptibility genes. Endocrinology 2002; 143: 2029-2040. (Pubitemid 34521549)
113. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, et al: Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299-1304, erratum 2002; 7: 215, 2004; 75: 1158. (Pubitemid 34450579)
114. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, et al: African-American heredity prostate cancer study: A model for genetic research. J Natl Med Assoc 2001; 93: 120-123.
115. Thompson AK, Shaw DI, Minihane AM, Williams CM: Trans-fatty acids and cancer: The evidence reviewed. Nutr Res Rev 2008; 21: 174-188.
116. Liu X, Schumacher FR, Plummer SJ, Jorgenson E, Casey G, Witte JS: Trans-fatty acid intake and increased risk of advanced prostate cancer: Modification by RNASEL R462Q variant. Carcinogenesis 2007; 28: 1232-1236. (Pubitemid 47062681)
117. Pierce BL, Ahsan H: Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 2010; 69: 193-201.
118. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, et al: Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008; 19: 1267-1276.
119. Gong ZH, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al: Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983. (Pubitemid 44664277)
120. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE: Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152. (Pubitemid 40096789)
121. Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, Coker AL, et al: Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev 2010; 19: 558-565.
122. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, et al: Screen-detected prostate cancer and the insulinlike growth factor axis: Results of a population-based case-control study. Int J Cancer 2004; 108: 887-892. (Pubitemid 38112619)
123. Li L, Yu H, Schumacher F, Casey G, Witte JS: Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003; 14: 721-726. (Pubitemid 37463885)
124. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, et al: Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 421-427. (Pubitemid 32701626)
125. Haldorsen IS, Vesterhus M, Raeder H, Jensen DK, Sovik O, Molven A, et al: Lack of pancreatic body and tail in HNF1B mutation carriers. Diabetic Med 2008; 25: 782-787.
126. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983. (Pubitemid 47185170)
127. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al: Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007; 56: 685-693. (Pubitemid 46348464)
128. Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Pate AV, et al: HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010; 70: 601-607.
129. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al: Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315. (Pubitemid 351311773)
130. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU: Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line. Biochim Biophys Acta 2005; 1731: 179-190. (Pubitemid 41735113)
131. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874-6879. (Pubitemid 30412807)
132. Adalat S, Woolf AS, Johnstone KA, Wirsing A, Harries LW, Long DA, et al: HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2009; 20: 1123-1131.
133. Michels AJ, Hagen TM: Hepatocyte nuclear factor 1 is essential for transcription of sodium-dependent vitamin C transporter protein 1. Am J Physiol Cell Physiol 2009; 297:C1220-C1227.
134. Power SC, Cereghini S: Positive regulation of the vHNF1 promoter by the orphan receptors COUP-TF1/Ear3 and COUP-TFII/Arp1. Mol Cell Biol 1996; 16: 778-791.
135. Hiesberger T, Shao X, Gourley E, Reimann A, Pontoglio M, Igarashi P: Role of the hepatocyte nuclear factor-1β (HNF- 1β ) C-terminal domain in Pkhd1 (ARPKD) gene transcription and renal cystogenesis. J Biol Chem 2005; 280: 10578-10586. (Pubitemid 40395919)
136. Manolio TA: Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363: 166-176.
137. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638-645. (Pubitemid 351601209)
138. Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, et al: Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev 2010; 19: 1349-1355.
139. Liu NC, Lin WJ, Kim E, Collins LL, Lin HY, Yu IC, et al: Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes 2007; 56: 2901-2909. (Pubitemid 350223624)
140. Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Hakimi P, et al: A mutation in the peroxisome proliferatoractivated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci USA 2002; 99: 625-630. (Pubitemid 34106562)
141. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, et al: Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101: 1272-1279.
142. Hsing AW, Chua S, Gao YT, Gentzschein E, Chang L, Deng J, et al: Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J Natl Cancer Inst 2001; 93: 783-789. (Pubitemid 32514802)
143. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG: Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 2002; 87: 726-728. (Pubitemid 35178749)
144. Asatiani E, Huang WX, Wang A, Ortner ER, Cavalli LR, Haddad BR, et al: Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 2005; 65: 1164-1173. (Pubitemid 40270140)
145. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al: Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999; 13: 966-977. (Pubitemid 29200980)
146. Muhlbradt E, Asatiani E, Ortner E, Wang A, Gelmann EP: NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation. Cancer Res 2009; 69: 2615-2622.
147. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB, Baltimore Longitudinal Study on Aging: Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258-4265. (Pubitemid 32055383)
148. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106. (Pubitemid 34830730)
149. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E: Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005; 16: 255-262. (Pubitemid 40897844)
150. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, et al: Plasma insulin-like growth factor-I, insulinlike growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 2000; 92: 1910-1917. (Pubitemid 32036921)
151. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R: High levels of circulating insulin-like growth factor- I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort. J Clin Oncol 2004; 22: 3104-3112. (Pubitemid 41103723)
152. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915. (Pubitemid 28304159)
153. Martel F, Azevedo I: An update on the extraneuronal monoamine transporter (EMT): Characteristics, distribution and regulation. Curr Drug Metab 2003; 4: 313-318. (Pubitemid 36958331)
154. Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, et al: Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. J Pharmacol Sci 2010; 113: 263-266.
155. 2+ movement in PC3 human prostate cancer cells. Pharmacol Res 2001; 44: 547-552.
156. Ohuchi Y, Yanai K, Sakurai E, Fukui H, Yanagisawa T, Watanabe T: Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors: A relationship between its sensitivity and the density of H1 receptors. Int J Mol Med 1998; 1: 355-360.
157. 2+ in cultured human keratinocytes. J Dermatol Sci 1999; 21: 127-132. (Pubitemid 29401979)
158. Kishi F, Nakaya Y, Ito S: Histamine H2-receptor-mediated nitric oxide release from porcine endothelial cells. J Cardiovasc Pharmacol 1998; 32: 177-182. (Pubitemid 28350635)
159. 2+ /calmodulin-dependent protein kinase II is stimulated by Wnt and frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem 2000; 275: 12701-12711. (Pubitemid 30241421)
160. Torres MA, YangSnyder JA, Purcell SM, DeMarais AA, McGrew LL, Moon RT: Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 1996; 133: 1123-1137. (Pubitemid 26172516)
161. Okamoto KI, Narayanan R, Lee SH, Murata K, Hayashi Y: The role of CaMKII as an F-actin-bundling protein crucial for maintenance of dendritic spine structure. Proc Natl Acad Sci USA 2007; 104: 6418-6423. (Pubitemid 47186109)
162. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG: Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 2008; 320: 365-369. (Pubitemid 351555657)
163. Brenner JC, Chinnaiyan AM: Translocations in epithelial cancers. Biochim Biophys Acta 2009; 1796: 201-215.
164. Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, et al: Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009; 48: 366-380.
165. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al: Androgen-induced TOP2B-mediated doublestrand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-675.
166. Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, et al: Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. Cancer Res 2009; 69: 640-646.
167. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, et al: Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007; 67: 8229-8239. (Pubitemid 47395160)
168. Mani R-S, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al: Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230.
169. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, et al: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009; 22: 1176-1185.
170. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, et al: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-513.
171. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al: Cooperativity of TMPRSS2-ERG with PI3- kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
172. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 18: 443-454.
173. Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, et al: ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010; 12: 1031-1040.
174. Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-C, et al: Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011; 21: 56-67.
175. Chinnaiyan AM, Palanisamy N: Chromosomal aberrations in solid tumors. Prog Mol Biol Transl Sci 2010; 95: 55-94.
176. Ferguson LR: Inhibitors of topoisomerase II enzymes: A unique group of environmental mutagens and carcinogens. Mutat Res 1998; 400: 271-278. (Pubitemid 28440229)
177. Ferguson LR: Chronic inflammation and mutagenesis. Mutat Res 2010; 690: 3-11.
178. Ferguson LR, Zhu S-T, Harris PJ: Antioxidant and antigenotoxic effects of plant cell wall hydroxycinnamic acids in cultured HT-29 cells. Mol Nutr Food Res 2005; 49: 585-593. (Pubitemid 40853704)
179. Karunasinghe N, Ryan J, Tuckey J, Masters J, Jamieson M, Clarke LC, et al: DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 391-397. (Pubitemid 38737464)
180. Philpott M, Ferguson LR, Gould KS, Harris PJ: Anthocyanidin-containing compounds occur in the periderm cell walls of the storage roots of sweet potato (Ipomoea batatas) J Plant Physiol 2009; 166: 1112-1117.
181. Philpott M, Lim CC, Ferguson LR: Dietary protection against free radicals: A case for multiple testing to establish structure-activity relationships for antioxidant potential of anthocyanic plant species. Int J Mol Sci 2009; 10: 1081-1103.
182. Fenech M, Ferguson LR: Vitamins/minerals and genomic stability in humans. Mutat Res 2001; 475: 1-6. (Pubitemid 32280798)
183. Ferguson LR: Role of plant polyphenols in genomic stability. Mutat Res 2001; 475: 89-111. (Pubitemid 32280805)
184. van Ommen B, Bouwman J, Dragsted LO, Drevon CA, Elliott R, de Groot P, et al: Challenges of molecular nutrition research 6: The nutritional phenotype database to store, share and evaluate nutritional systems biology studies. Genes Nutr 2010; 5: 189-203.
185. van Ommen B, El-Sohemy A, Hesketh J, Kaput J, Fenech M, Evelo CT, et al: The Micronutrient Genomics Project: A community-driven knowledge base for micronutrient research. Genes Nutr 2010; 5: 285-296.
186. Gillanders EM, Xu J, Chang B-l, Lange EM, Wiklund F, Bailey-Wilson JE, et al: Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004; 96: 1240-1247. (Pubitemid 39232715)
187. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, et al: Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2009; 18: 2528-2539.
188. Furusawa T, Moribe H, Kondoh H, Higashi Y: Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor δEF1. Mol Cell Biol 1999; 19: 8581-8590. (Pubitemid 30414051)
189. Johansson A, Marroni F, Hayward C, Franklin CS, Kirichenko AV, Jonasson I, et al: Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. Hum Mol Genet 2009; 18: 373-380.
190. Chang B-L, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, et al: Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009; 18: 1368-1375.
191. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, et al: The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 2010; 5:e13363.
192. Shimada T: Salivary proteins as a defense against dietary tannins. J Chem Ecol 2006; 32: 1149-1163. (Pubitemid 43892402)
193. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al: Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-1121.
194. Leslie NR, McLennan AG, Safrany ST: Cloning and characterisation of hAps1 and hAps2, human diadenosine polyphosphate- metabolising Nudix hydrolases. BMC Biochem 2002; 3: 20.
195. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, et al: Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev 2009; 18: 1285-1289.